Related references
Note: Only part of the references are listed.Astragaloside VI Promotes Neural Stem Cell Proliferation and Enhances Neurological Function Recovery in Transient Cerebral Ischemic Injuryvia Activating EGFR/MAPK Signaling Cascades
Xi Chen et al.
MOLECULAR NEUROBIOLOGY (2019)
Protective effects of Astragaloside IV on endoplasmic reticulum stress-induced renal tubular epithelial cells apoptosis in type 2 diabetic nephropathy rats
Yinghui Ju et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Astragaloside IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats
Yuyan Fan et al.
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2019)
Astragaloside IV/lncRNA-TUGI/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats
Xiao Lei et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Combination of Ginsenoside Rg1 and Astragaloside IV reduces oxidative stress and inhibits TGF-β1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy
Na Du et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
DMP-1 attenuates oxidative stress and inhibits TGF-β activation in rats with diabetic kidney disease
Na Du et al.
RENAL FAILURE (2017)
The role of the complement system in diabetic nephropathy
Allan Flyvbjerg
NATURE REVIEWS NEPHROLOGY (2017)
Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network
Xinhui Liu et al.
PLOS ONE (2017)
Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy
Hengjiang Guo et al.
SCIENTIFIC REPORTS (2017)
Diabetic nephropathy: New insights into established therapeutic paradigms and novel molecular targets
Dilip Sharma et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Cyclocarya paliurus extract alleviates diabetic nephropathy by inhibiting oxidative stress and aldose reductase
XiaoHong Wang et al.
RENAL FAILURE (2016)
Astragaloside IV Attenuates Podocyte Apoptosis Mediated by Endoplasmic Reticulum Stress through Upregulating Sarco/Endoplasmic Reticulum Ca2+-ATPase 2 Expression in Diabetic Nephropathy
Hengjiang Guo et al.
FRONTIERS IN PHARMACOLOGY (2016)
Astragaloside IV ameliorates renal injury in db/db mice
Huili Sun et al.
SCIENTIFIC REPORTS (2016)
US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States (vol 66, pg S1, 2015)
R. Saran et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
the National Institutes of Health and guidance for reporting preclinical research (vol 13, pg 34, 2015)
David Moher et al.
BMC MEDICINE (2015)
Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress
Zeng Si Wang et al.
BMC NEPHROLOGY (2015)
US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States
Rajiv Saran et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
SYRCLE's risk of bias tool for animal studies
Carlijn R. Hooijmans et al.
BMC MEDICAL RESEARCH METHODOLOGY (2014)
Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats
Jianguo Chen et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Therapeutic approaches to diabetic nephropathy-beyond the RAS
Beatriz Fernandez-Fernandez et al.
NATURE REVIEWS NEPHROLOGY (2014)
Publication bias in the social sciences: Unlocking the file drawer
Annie Franco et al.
SCIENCE (2014)
Early diabetic nephropathy in type 1 diabetes: new insights
Petter Bjornstad et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2014)
Astragaloside IV prevents acute kidney injury in two rodent models by inhibiting oxidative stress and apoptosis pathways
Dingkun Gui et al.
APOPTOSIS (2013)
Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression
Dingkun Gui et al.
CYTOKINE (2013)
Towards Evidence-Based Translational Research: The pros and cons of conducting systematic reviews of animal studies
Judith van Luijk et al.
ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION (2013)
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update Foreword
Michael V. Rocco et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2012)
Astragaloside IV, a Novel Antioxidant, Prevents Glucose-Induced Podocyte Apoptosis In Vitro and In Vivo
Dingkun Gui et al.
PLOS ONE (2012)
Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy
G. H. Tesch et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2011)
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Carol Kilkenny et al.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2010)
Absorption enhancement study of astragaloside IV based on its transport mechanism in Caco-2 cells
C. R. Huang et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2006)
Transport and bioavailability studies of astragaloside IV, an active ingredient in Radix Astragali
YC Gu et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2004)
Pooling of animal experimental data reveals influence of study design and publication bias
MR Macleod et al.
STROKE (2004)
Diabetic kidney disease in the db/db mouse
K Sharma et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2003)
Share Paper
